These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 26233582)

  • 1. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program.
    Odin P; Ray Chaudhuri K; Slevin JT; Volkmann J; Dietrichs E; Martinez-Martin P; Krauss JK; Henriksen T; Katzenschlager R; Antonini A; Rascol O; Poewe W;
    Parkinsonism Relat Disord; 2015 Oct; 21(10):1133-44. PubMed ID: 26233582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach.
    Antonini A; Stoessl AJ; Kleinman LS; Skalicky AM; Marshall TS; Sail KR; Onuk K; Odin PLA
    Curr Med Res Opin; 2018 Dec; 34(12):2063-2073. PubMed ID: 30016901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease--Clinical practice recommendations.
    Trenkwalder C; Chaudhuri KR; García Ruiz PJ; LeWitt P; Katzenschlager R; Sixel-Döring F; Henriksen T; Sesar Á; Poewe W; ; Baker M; Ceballos-Baumann A; Deuschl G; Drapier S; Ebersbach G; Evans A; Fernandez H; Isaacson S; van Laar T; Lees A; Lewis S; Martínez Castrillo JC; Martinez-Martin P; Odin P; O'Sullivan J; Tagaris G; Wenzel K
    Parkinsonism Relat Disord; 2015 Sep; 21(9):1023-30. PubMed ID: 26189414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. European Academy of Neurology/Movement Disorder Society-European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive Therapies.
    Deuschl G; Antonini A; Costa J; Śmiłowska K; Berg D; Corvol JC; Fabbrini G; Ferreira J; Foltynie T; Mir P; Schrag A; Seppi K; Taba P; Ruzicka E; Selikhova M; Henschke N; Villanueva G; Moro E
    Mov Disord; 2022 Jul; 37(7):1360-1374. PubMed ID: 35791767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practical approaches to commencing device-assisted therapies for Parkinson disease in Australia.
    Williams DR; Evans AH; Fung VSC; Hayes M; Iansek R; Kimber T; O'Sullivan JD; Sue CM
    Intern Med J; 2017 Oct; 47(10):1107-1113. PubMed ID: 28195385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Motor features and response to oral levodopa in patients with Parkinson's disease under continuous dopaminergic infusion or deep brain stimulation.
    Elia AE; Dollenz C; Soliveri P; Albanese A
    Eur J Neurol; 2012 Jan; 19(1):76-83. PubMed ID: 21645174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Device-Aided Treatment Strategies in Advanced Parkinson's Disease.
    Timpka J; Nitu B; Datieva V; Odin P; Antonini A
    Int Rev Neurobiol; 2017; 132():453-474. PubMed ID: 28554418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Effectiveness of Carbidopa/Levodopa Enteral Suspension and Deep Brain Stimulation on Pill Burden Reduction in Medicare Fee-for-Service Patients with Advanced Parkinson's Disease.
    Soileau MJ; Pagan FL; Fasano A; Rodriguez-Cruz R; Yan CH; Gupta NR; Teigland CL; Pulungan Z; Schinkel JK; Kandukuri PL; Ladhani OA; Siddiqui MS
    Neurol Ther; 2023 Apr; 12(2):459-478. PubMed ID: 36652111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. European Academy of Neurology/Movement Disorder Society - European Section guideline on the treatment of Parkinson's disease: I. Invasive therapies.
    Deuschl G; Antonini A; Costa J; Śmiłowska K; Berg D; Corvol JC; Fabbrini G; Ferreira J; Foltynie T; Mir P; Schrag A; Seppi K; Taba P; Ruzicka E; Selikhova M; Henschke N; Villanueva G; Moro E
    Eur J Neurol; 2022 Sep; 29(9):2580-2595. PubMed ID: 35791766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of subcutaneous infusion of apomorphine in Parkinson's disease.
    Wenzel K; Homann CN; Fabbrini G; Colosimo C
    Expert Rev Neurother; 2014 Jul; 14(7):833-43. PubMed ID: 24917215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Device-Aided Therapies in Parkinson's Disease: A Structured Review.
    Smilowska K; van Wamelen DJ; Pietrzykowski T; Calvano A; Rodriguez-Blazquez C; Martinez-Martin P; Odin P; Chaudhuri KR
    J Parkinsons Dis; 2021; 11(2):475-489. PubMed ID: 33386813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. When the going gets tough: how to select patients with Parkinson's disease for advanced therapies.
    Worth PF
    Pract Neurol; 2013 Jun; 13(3):140-52. PubMed ID: 23487815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Device-aided therapies for advanced Parkinson disease: insights from an international survey.
    Marsili L; Bologna M; Miyasaki JM; Colosimo C
    Neurol Sci; 2021 Jul; 42(7):2961-2964. PubMed ID: 33550525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Application of levodopa/carbidopa intestinal gel in advanced Parkinson's disease].
    Toth A; Nagy H; Wacha J; Bereczki D; Takáts A
    Neuropsychopharmacol Hung; 2015 Dec; 17(4):191-6. PubMed ID: 26727723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review.
    Volkmann J; Albanese A; Antonini A; Chaudhuri KR; Clarke CE; de Bie RM; Deuschl G; Eggert K; Houeto JL; Kulisevsky J; Nyholm D; Odin P; Østergaard K; Poewe W; Pollak P; Rabey JM; Rascol O; Ruzicka E; Samuel M; Speelman H; Sydow O; Valldeoriola F; van der Linden C; Oertel W
    J Neurol; 2013 Nov; 260(11):2701-14. PubMed ID: 23287972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced Parkinson's disease: clinical characteristics and treatment. Part II.
    Kulisevsky J; Luquin MR; Arbelo JM; Burguera JA; Carrillo F; Castro A; Chacón J; García-Ruiz PJ; Lezcano E; Mir P; Martinez-Castrillo JC; Martínez-Torres I; Puente V; Sesar A; Valldeoriola-Serra F; Yañez R
    Neurologia; 2013; 28(9):558-83. PubMed ID: 23880230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficiency and safety of bilateral contemporaneous pallidal stimulation (deep brain stimulation) in levodopa-responsive patients with Parkinson's disease with severe motor fluctuations: a 2-year follow-up review.
    Ghika J; Villemure JG; Fankhauser H; Favre J; Assal G; Ghika-Schmid F
    J Neurosurg; 1998 Nov; 89(5):713-8. PubMed ID: 9817406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
    Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parkinson's Disease: Personalized Pathway of Care for Device-Aided Therapies (DAT) and the Role of Continuous Objective Monitoring (COM) Using Wearable Sensors.
    Metta V; Batzu L; Leta V; Trivedi D; Powdleska A; Mridula KR; Kukle P; Goyal V; Borgohain R; Chung-Faye G; Chaudhuri KR
    J Pers Med; 2021 Jul; 11(7):. PubMed ID: 34357147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.
    Honig H; Antonini A; Martinez-Martin P; Forgacs I; Faye GC; Fox T; Fox K; Mancini F; Canesi M; Odin P; Chaudhuri KR
    Mov Disord; 2009 Jul; 24(10):1468-74. PubMed ID: 19425079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.